Hacettepe University Faculty of Medicine, Division of Hematology, Ankara, Turkey
Erciyes University Faculty of Medicine, Division of Hematology, Kayseri, Turkey
Turk J Haematol. 2022 Aug 25;39(3):152-159. doi: 10.4274/tjh.galenos.2022.2021.0680. Epub 2022 Apr 21.
Studies comparing the efficacy and safety of prophylactic regimens for central nervous system (CNS) involvement in acute lymphoblastic leukemia (ALL) are scarce in adults. This multicenter retrospective study aimed to compare the efficacy of prophylactic regimens with and without CNS irradiation on the development of CNS relapse during follow-up.
This was a multicenter comparative cohort study. A total of 203 patients were included from four tertiary care centers in Turkey. Patients were divided into two groups according to whether they received CNS irradiation or not. The groups were analyzed retrospectively regarding patient and disease characteristics, with the main focus being CNS relapse.
While 105 patients received chemotherapy-based prophylaxis, 98 patients received additional CNS irradiation. These groups were statistically comparable in terms of demographic characteristics and risk factors for CNS involvement. In the irradiation group, patients were younger and had more stem cell transplants. In a median of 23.8 (11.1-62.4) months, there was no difference between the two groups regarding CNS relapse-free survival (log-rank p=0.787).
Craniospinal irradiation may not be indispensable for every adult patient with ALL, similarly to pediatric patients. It is crucial to avoid the long-term toxicities of radiation, especially in patients with long life expectancy. Craniospinal irradiation may be reserved for therapeutic use in cases of CNS relapse and prophylaxis for some high-risk patients.
成人急性淋巴细胞白血病(ALL)中枢神经系统(CNS)受累预防性方案的疗效和安全性比较研究较为匮乏。本多中心回顾性研究旨在比较有无 CNS 放疗的预防性方案在随访期间 CNS 复发发展方面的疗效。
这是一项多中心比较队列研究。共纳入来自土耳其四家三级护理中心的 203 例患者。根据是否接受 CNS 放疗,患者分为两组。对两组患者的临床和疾病特征进行回顾性分析,主要关注点为 CNS 复发。
105 例患者接受基于化疗的预防方案,98 例患者接受额外的 CNS 放疗。两组在人口统计学特征和 CNS 受累风险因素方面具有可比性。在中位时间为 23.8(11.1-62.4)个月时,两组 CNS 无复发生存率(对数秩检验 p=0.787)无差异。
与儿科患者类似,对于大多数 ALL 成年患者,颅脑脊髓放疗可能并非必不可少。避免放疗的长期毒性作用至关重要,尤其是对于预期寿命较长的患者。对于 CNS 复发,颅脑脊髓放疗可保留作为治疗手段,对于某些高危患者,可保留作为预防措施。